Skip to main content
. 2021 Apr 29;11(5):809. doi: 10.3390/diagnostics11050809

Figure 2.

Figure 2

96-week intention-to-treat efficacy of two-drug regimens in virologically suppressed patients in clinical trials. Histograms represent individual studies—not a head-to-head comparison. 3TC = lamivudine; ATV/r = ritonavir-boosted atazanavir; cART = combination antiretroviral therapy; DTG = dolutegravir; DRV/r = ritonavir-boosted darunavir; NI = noninferior treatment difference; RPV = rilpivirine; TAF = tenofovir alafenamide.